Werewolf Therapeutics, Inc.
Data quality: 83%
HOWL
Nasdaq
Manufacturing
Chemicals
$0.90
▼
$0.08
(-8.21%)
Mkt Cap: 43.91 M
Price
$0.90
Mkt Cap
43.91 M
Day Range
$0.88 — $0.98
52-Week Range
$0.53 — $2.38
Volume
184,873
Open $0.98
50D / 200D Avg
$0.73
24.46% above
50D / 200D Avg
$1.10
17.70% below
Quick Summary
Key Takeaways
Negative free cash flow of -60.29 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-171.14%
Below sector avg (-51.02%)
ROIC-68.76%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
1.08
Above sector avg (0.33)
Current Ratio3.87
Interest Coverage-11.50
Valuation
PE (TTM)
-0.72
Above sector avg (-1.98)
P/B Ratio1.48
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.7 | -2.0 |
| P/B | 1.5 | 5.1 |
| ROE % | -171.1 | -51.0 |
| Net Margin % | — | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | 1.1 | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -60.82 M |
| ROE | -171.14% | ROA | -70.64% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -60.29 M |
| ROIC | -68.76% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1.08 | Current Ratio | 3.87 |
| Interest Coverage | -11.50 | Asset Turnover | N/A |
| Working Capital | 50.57 M | Tangible Book Value | 29.61 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.72 | Forward P/E | N/A |
| P/B Ratio | 1.48 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -137.30% | ||
| Market Cap | 43.91 M | Enterprise Value | 10.29 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.33 | Revenue / Share | N/A |
| FCF / Share | -1.24 | OCF / Share | -1.24 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 99.13% |
| SBC-Adj. FCF | -67.34 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -60.82 M | -70.52 M | -37.37 M | -53.81 M | -49.98 M |
| EPS (Diluted) | -1.33 | -1.63 | -1.05 | -1.86 | -10.94 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -60.68 M | -73.59 M | -40.50 M | -56.06 M | -50.09 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 44.83 M | 56.43 M | 41.78 M | 53.76 M | 35.27 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 5.27 M | 3.31 M | 3.14 M | — | — |
| Income Tax | 0.0 | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 69.40 M | 126.93 M | 174.83 M | 160.25 M | 179.25 M |
| Total Liabilities | 44.59 M | 53.54 M | 63.46 M | 37.91 M | 26.46 M |
| Shareholders' Equity | 24.81 M | 73.39 M | 111.37 M | 122.34 M | 152.79 M |
| Total Debt | 32.09 M | 32.09 M | 40.00 M | — | — |
| Cash & Equivalents | 57.05 M | 111.00 M | 134.34 M | 129.32 M | 157.53 M |
| Current Assets | 58.59 M | 113.07 M | 138.37 M | 140.20 M | 161.07 M |
| Current Liabilities | 36.15 M | 15.18 M | 19.38 M | 23.99 M | 11.87 M |
{"event":"ticker_viewed","properties":{"ticker":"HOWL","listing_kind":"stock","pathname":"/stocks/howl","exchange":"Nasdaq","country":"US"}}